Press Release

Evrysdi™ Approved for Spinal Muscular Atrophy Home Treatment

The FDA has approved Evrysdi™ (risdiplam), the first at-home, orally administered treatment for spinal muscular atrophy in children and adults

4 years ago

FDA Approves New Opioid, Olinvyk, for Intravenous Use in Hospitals

the U.S. Food and Drug Administration approved Olinvyk (oliceridine), an opioid agonist for the management of moderate to severe acute…

4 years ago

Impact of COVID-19 on the Respiratory Device Accessories Market

This report is built to visualize quantitative market trends within Anesthesia and Respiratory Devices therapeutic area. The model discusses in…

4 years ago

INOVIO’s COVID-19 Vaccine Shows Durable Antibody and T Cell Responses

INOVIO's COVID-19 DNA Vaccine INO-4800 Provides Protection with Memory Immune Responses In Non-Human Primates Challenged with SARS-CoV-2 Virus

4 years ago

INOVIO Receives $71 Million Contract From U.S. Department of Defense

CELLECTRA® 3PSP is designed to deliver INO-4800 directly into the skin, where the vaccine prompts the body's immune system to…

4 years ago

FDA approves Ready-to-Use Ephedrine Injection, Emerphed™

Nexus Pharmaceuticals, Inc. Announces Approval of Emerphed™ (ephedrine sulfate) Injection, the First and Only FDA-approved, Ready-to-Use Ephedrine Injection (50 mg/10…

4 years ago

AURA™ adds Protein/Non Protein Identification to Horizon®

Aura revolutionizes biologic stability analysis, enabling simple protein and non-protein aggregate identification in formulation development and analytical testing

4 years ago

COVID-19 Testing with 72 Hour or Less Turnaround Time

TCA/GENETWORx is building capability to perform 870,000 tests per day or 26 million per month. In order to meet demand,…

4 years ago

First NASH Patient Dosed with CRV431 in Phase 2 ‘AMBITION’ Clinical Trial

The ‘AMBITION' trial, is designed to assess safety, tolerability, and pharmacokinetics of 75 mg CRV431, administered orally to F2 and…

4 years ago

Hepion Pharmaceuticals’ CRV431 Demonstrates Efficacy in Kidney Fibrosis

CRV431 has exerted antifibrotic activity in a number of in vitro and in vivo studies conducted by independent research laboratories

4 years ago

This website uses cookies. Your continued use of the site is subject to the acceptance of these cookies. Please refer to our Privacy Policy for more information.

Read More